Solid Biosciences (SLDB) Prices 21.74M Share Common Offering at $5.75/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
Solid Biosciences Announces Pricing of Public Offering of Common Stock
March 18, 2021 9:14 PM EDTCAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc., (Nasdaq: SLDB) a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it has priced an underwritten public offering of 21,739,131 shares of its common stock at a public offering price of $5.75 per share, for total gross proceeds of $125.0 million, before deducting underwriting discounts and commissions and offering expenses. In addition, Solid has granted the underwriters a 30-day option to purchase up to an additional 3,260,869 shares of its common stock on the same terms and conditions.... More



